

Shin-ichi Tsunoda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8760063/publications.pdf>

Version: 2024-02-01

111
papers

4,743
citations

93792

39
h-index

116156

66
g-index

123
all docs

123
docs citations

123
times ranked

7124
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of a TNFR2-Selective Agonistic TNF- $\hat{I}\pm$ Mutant and Its Derivatives as an Optimal Regulatory T Cell Expander. <i>Journal of Immunology</i> , 2021, 206, 1740-1751.	0.4	12
2	Structural optimization of a TNFR1-selective antagonistic TNF $\hat{I}\pm$ mutant to create new-modality TNF-regulating biologics. <i>Journal of Biological Chemistry</i> , 2020, 295, 9379-9391.	1.6	7
3	A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer. <i>Scientific Reports</i> , 2019, 9, 7618.	1.6	24
4	Neutrophil Depletion Exacerbates Pregnancy Complications, Including Placental Damage, Induced by Silica Nanoparticles in Mice. <i>Frontiers in Immunology</i> , 2018, 9, 1850.	2.2	17
5	A trimeric structural fusion of an antagonistic tumor necrosis factor- $\hat{I}\pm$ mutant enhances molecular stability and enables facile modification. <i>Journal of Biological Chemistry</i> , 2017, 292, 6438-6451.	1.6	14
6	Identifying a size-specific hazard of silica nanoparticles after intravenous administration and its relationship to the other hazards that have negative correlations with the particle size in mice. <i>Nanotechnology</i> , 2017, 28, 135101.	1.3	15
7	Modifying the Surface of Silica Nanoparticles with Amino or Carboxyl Groups Decreases Their Cytotoxicity to Parenchymal Hepatocytes. <i>Biological and Pharmaceutical Bulletin</i> , 2017, 40, 726-728.	0.6	7
8	Creation of mouse TNFR2-selective agonistic TNF mutants using a phage display technique. <i>Biochemistry and Biophysics Reports</i> , 2016, 7, 309-315.	0.7	7
9	A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy. <i>PLoS ONE</i> , 2015, 10, e0144712.	1.1	39
10	Protein corona changes mediated by surface modification of amorphous silica nanoparticles suppress acute toxicity and activation of intrinsic coagulation cascade in mice. <i>Nanotechnology</i> , 2015, 26, 245101.	1.3	47
11	Identification and evaluation of metastasis-related proteins, oxysterol binding protein-like 5 and calumenin, in lung tumors. <i>International Journal of Oncology</i> , 2015, 47, 195-205.	1.4	50
12	Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3. <i>Biochemical and Biophysical Research Communications</i> , 2015, 456, 908-912.	1.0	16
13	Aminopeptidase P3 (APP3), a novel member of the TNF/TNFR2 signaling complex, induces phosphorylation of JNK. <i>Journal of Cell Science</i> , 2015, 128, 656-69.	1.2	18
14	Cutaneous exposure to agglomerates of silica nanoparticles and allergen results in IgE-biased immune response and increased sensitivity to anaphylaxis in mice. <i>Particle and Fibre Toxicology</i> , 2015, 12, 16.	2.8	22
15	Size and surface modification of amorphous silica particles determine their effects on the activity of human CYP3A4 in vitro. <i>Nanoscale Research Letters</i> , 2014, 9, 651.	3.1	14
16	The Absorption, Distribution, Metabolism, and Excretion Profile of Nanoparticles. <i>Nanomedicine and Nanotoxicology</i> , 2014, , 259-271.	0.1	4
17	Intestinal absorption and biological effects of orally administered amorphous silica particles. <i>Nanoscale Research Letters</i> , 2014, 9, 532.	3.1	49
18	Evaluation of silica nanoparticle binding to major human blood proteins. <i>Nanoscale Research Letters</i> , 2014, 9, 2493.	3.1	24

#	ARTICLE	IF	CITATIONS
19	Asian Dust Particles Induce Macrophage Inflammatory Responses via Mitogen-Activated Protein Kinase Activation and Reactive Oxygen Species Production. <i>Journal of Immunology Research</i> , 2014, 2014, 1-9.	0.9	15
20	Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers. <i>Journal of Controlled Release</i> , 2014, 189, 72-79.	4.8	44
21	Eph receptor A10 has a potential as a target for a prostate cancer therapy. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 545-549.	1.0	27
22	Intranasal exposure to amorphous nanosilica particles could activate intrinsic coagulation cascade and platelets in mice. <i>Particle and Fibre Toxicology</i> , 2013, 10, 41.	2.8	61
23	Mutants of lymphotoxin- β with augmented cytotoxic activity via TNFR1 for use in cancer therapy. <i>Cytokine</i> , 2013, 61, 578-584.	1.4	4
24	Proteomic analysis of the hippocampus in Alzheimer's disease model mice by using two-dimensional fluorescence difference in gel electrophoresis. <i>Neuroscience Letters</i> , 2013, 534, 85-89.	1.0	38
25	Liver-specific microRNAs as biomarkers of nanomaterial-induced liver damage. <i>Nanotechnology</i> , 2013, 24, 405102.	1.3	49
26	Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients. <i>Cancer Medicine</i> , 2013, 2, 972-977.	1.3	34
27	Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody. <i>Blood</i> , 2013, 121, 2804-2813.	0.6	30
28	Carbon Nanomaterials: Efficacy and Safety for Nanomedicine. <i>Materials</i> , 2012, 5, 350-363.	1.3	65
29	Amorphous nanosilicas induce consumptive coagulopathy after systemic exposure. <i>Nanotechnology</i> , 2012, 23, 045101.	1.3	62
30	Suppression of nanosilica particle-induced inflammation by surface modification of the particles. <i>Archives of Toxicology</i> , 2012, 86, 1297-1307.	1.9	49
31	Distribution and histologic effects of intravenously administered amorphous nanosilica particles in the testes of mice. <i>Biochemical and Biophysical Research Communications</i> , 2012, 420, 297-301.	1.0	68
32	Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 421, 140-144.	1.0	25
33	Hemopexin as biomarkers for analyzing the biological responses associated with exposure to silica nanoparticles. <i>Nanoscale Research Letters</i> , 2012, 7, 555.	3.1	15
34	Amorphous silica nanoparticles enhance cross-presentation in murine dendritic cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 427, 553-556.	1.0	40
35	Surface modification of amorphous nanosilica particles suppresses nanosilica-induced cytotoxicity, ROS generation, and DNA damage in various mammalian cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 427, 748-752.	1.0	51
36	Amorphous silica nanoparticles size-dependently aggravate atopic dermatitis-like skin lesions following an intradermal injection. <i>Particle and Fibre Toxicology</i> , 2012, 9, 3.	2.8	75

#	ARTICLE	IF	CITATIONS
37	Lysine-deficient lymphotoxin- β mutant for site-specific PEGylation. <i>Cytokine</i> , 2011, 56, 489-493.	1.4	3
38	Limited expression of reticulocalbin-1 in lymphatic endothelial cells in lung tumor but not in normal lung. <i>Biochemical and Biophysical Research Communications</i> , 2011, 405, 610-614.	1.0	8
39	Structure-activity relationship of T-cell receptors based on alanine scanning. <i>Biochemical and Biophysical Research Communications</i> , 2011, 415, 558-562.	1.0	2
40	Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. <i>Nature Nanotechnology</i> , 2011, 6, 321-328.	15.6	622
41	Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice. <i>Journal of Controlled Release</i> , 2011, 149, 8-14.	4.8	49
42	Effect of amorphous silica nanoparticles on in vitro RANKL-induced osteoclast differentiation in murine macrophages. <i>Nanoscale Research Letters</i> , 2011, 6, 464.	3.1	19
43	Modifying the antigen-immunization schedule improves the variety of monoclonal antibodies obtained from immune-phage antibody libraries against HIV-1 Nef and Vif. <i>Journal of Bioscience and Bioengineering</i> , 2011, 111, 597-599.	1.1	4
44	Acute phase proteins as biomarkers for predicting the exposure and toxicity of nanomaterials. <i>Biomaterials</i> , 2011, 32, 3-9.	5.7	54
45	Development of an antibody proteomics system using a phage antibody library for efficient screening of biomarker proteins. <i>Biomaterials</i> , 2011, 32, 162-169.	5.7	31
46	Promotion of allergic immune responses by intranasally-administrated nanosilica particles in mice. <i>Nanoscale Research Letters</i> , 2011, 6, 195.	3.1	50
47	Effect of surface properties of silica nanoparticles on their cytotoxicity and cellular distribution in murine macrophages. <i>Nanoscale Research Letters</i> , 2011, 6, 93.	3.1	71
48	Amorphous nanosilica induce endocytosis-dependent ROS generation and DNA damage in human keratinocytes. <i>Particle and Fibre Toxicology</i> , 2011, 8, 1.	2.8	229
49	Development of a novel DDS for site-specific PEGylated proteins. <i>Chemistry Central Journal</i> , 2011, 5, 25.	2.6	9
50	Systemic distribution, nuclear entry and cytotoxicity of amorphous nanosilica following topical application. <i>Biomaterials</i> , 2011, 32, 2713-2724.	5.7	161
51	Fine tuning of receptor-selectivity for tumor necrosis factor- β using a phage display system with one-step competitive panning. <i>Biomaterials</i> , 2011, 32, 5498-5504.	5.7	15
52	Identification of New Candidates as Mucosal Vaccine Adjuvant in TNF Family Cytokines. <i>Advances in Experimental Medicine and Biology</i> , 2011, 691, 299-304.	0.8	1
53	Anti-inflammatory Effects of a Novel TNFR1-Selective Antagonistic TNF Mutant on Established Murine Collagen-Induced Arthritis. <i>Advances in Experimental Medicine and Biology</i> , 2011, 691, 493-500.	0.8	5
54	Development of functional cytokine mutants by molecular evolution and drug delivery technology. <i>Drug Delivery System</i> , 2011, 26, 604-610.	0.0	0

#	ARTICLE	IF	CITATIONS
55	Interleukin-1 Family Cytokines as Mucosal Vaccine Adjuvants for Induction of Protective Immunity against Influenza Virus. <i>Journal of Virology</i> , 2010, 84, 12703-12712.	1.5	109
56	Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy. <i>Biomaterials</i> , 2010, 31, 3357-3363.	5.7	13
57	Carbon Nanotubes Elicit DNA Damage and Inflammatory Response Relative to Their Size and Shape. <i>Inflammation</i> , 2010, 33, 276-280.	1.7	143
58	Creation of lysine-deficient mutant lymphotoxin- β with receptor selectivity by using a phage display system. <i>Biomaterials</i> , 2010, 31, 1935-1943.	5.7	12
59	The effect of surface modification of amorphous silica particles on NLRP3 inflammasome mediated IL-1 β production, ROS production and endosomal rupture. <i>Biomaterials</i> , 2010, 31, 6833-6842.	5.7	136
60	Comparison of the anti-tumor activity of native, secreted, and membrane-bound LIGHT in mouse tumor models. <i>International Immunopharmacology</i> , 2010, 10, 26-33.	1.7	2
61	Generation of mouse macrophages expressing membrane-bound TNF variants with selectivity for TNFR1 or TNFR2. <i>Cytokine</i> , 2010, 50, 75-83.	1.4	5
62	Titanium dioxide induces different levels of IL-1 β production dependent on its particle characteristics through caspase-1 activation mediated by reactive oxygen species and cathepsin B. <i>Biochemical and Biophysical Research Communications</i> , 2010, 392, 160-165.	1.0	83
63	Creation of a lysine-deficient LIGHT mutant with the capacity for site-specific PEGylation and low affinity for a decoy receptor. <i>Biochemical and Biophysical Research Communications</i> , 2010, 393, 888-893.	1.0	10
64	Solution of the Structure of the TNF-TNFR2 Complex. <i>Science Signaling</i> , 2010, 3, ra83.	1.6	171
65	Development of functional cytokines as novel mucosal vaccine adjuvants. <i>Drug Delivery System</i> , 2010, 25, 22-28.	0.0	1
66	A Novel Tumor-Targeted Therapy Using a Claudin-4-Targeting Molecule. <i>Molecular Pharmacology</i> , 2009, 76, 918-926.	1.0	71
67	The use of a mutant TNF- β as a vaccine adjuvant for the induction of mucosal immune responses. <i>Biomaterials</i> , 2009, 30, 5869-5876.	5.7	33
68	Crystallization and preliminary X-ray analysis of the tumour necrosis factor β -tumour necrosis factor receptor type 2 complex. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2009, 65, 295-298.	0.7	10
69	The augmentation of intracellular delivery of peptide therapeutics by artificial protein transduction domains. <i>Biomaterials</i> , 2009, 30, 3318-3323.	5.7	9
70	The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. <i>Biomaterials</i> , 2009, 30, 6638-6647.	5.7	50
71	LIGHT protein suppresses tumor growth by augmentation of immune response. <i>Immunology Letters</i> , 2009, 127, 33-38.	1.1	9
72	Silica nanoparticles as hepatotoxicants. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2009, 72, 496-501.	2.0	209

#	ARTICLE	IF	CITATIONS
73	Histological analysis of 70-nm silica particles-induced chronic toxicity in mice. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2009, 72, 626-629.	2.0	80
74	TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant. <i>Biochemical and Biophysical Research Communications</i> , 2009, 384, 296-300.	1.0	16
75	Novel protein engineering strategy for creating highly receptor-selective mutant TNFs. <i>Biochemical and Biophysical Research Communications</i> , 2009, 388, 667-671.	1.0	7
76	Structure-Function Relationship of Tumor Necrosis Factor (TNF) and Its Receptor Interaction Based on 3D Structural Analysis of a Fully Active TNFR1-Selective TNF Mutant. <i>Journal of Molecular Biology</i> , 2009, 385, 1221-1229.	2.0	65
77	Fast Binding Kinetics and Conserved 3D Structure Underlie the Antagonistic Activity of Mutant TNF: Useful Information for Designing Artificial Proteo-Antagonists. <i>Journal of Biochemistry</i> , 2009, 146, 167-172.	0.9	15
78	Arsenic Trioxide Inhibits Human T Cell-Lymphotropic Virus-1-Induced Syncytiums by Down-Regulating gp46. <i>Biological and Pharmaceutical Bulletin</i> , 2009, 32, 1286-1288.	0.6	2
79	Domain mapping of a claudin-4 modulator, the C-terminal region of C-terminal fragment of <i>Clostridium perfringens</i> enterotoxin, by site-directed mutagenesis. <i>Biochemical Pharmacology</i> , 2008, 75, 1639-1648.	2.0	73
80	Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity. <i>Journal of Immunological Methods</i> , 2008, 335, 71-78.	0.6	11
81	Organelle-Targeted Delivery of Biological Macromolecules Using the Protein Transduction Domain: Potential Applications for Peptide Aptamer Delivery into the Nucleus. <i>Journal of Molecular Biology</i> , 2008, 380, 777-782.	2.0	24
82	Ligand-independent assembly of purified soluble magic roundabout (Robo4), a tumor-specific endothelial marker. <i>Protein Expression and Purification</i> , 2008, 61, 78-82.	0.6	4
83	The therapeutic effect of TNFR1-selective antagonistic mutant TNF- Δ in murine hepatitis models. <i>Cytokine</i> , 2008, 44, 229-233.	1.4	47
84	Creation and X-ray Structure Analysis of the Tumor Necrosis Factor Receptor-1-selective Mutant of a Tumor Necrosis Factor- Δ Antagonist. <i>Journal of Biological Chemistry</i> , 2008, 283, 998-1007.	1.6	89
85	3P-081 Creation of TNFR1-selective mutant lymphotoxin alpha using phage display system(The 46th Tj ETQq1 1 0.784314 rgBT /Ove	0.0	0
86	Creation of Novel Cell-Penetrating Peptides for Intracellular Drug Delivery Using Systematic Phage Display Technology Originated from Tat Transduction Domain. <i>Biological and Pharmaceutical Bulletin</i> , 2007, 30, 218-223.	0.6	32
87	Improved cytosolic translocation and tumor-killing activity of Tat-shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide. <i>Biochemical and Biophysical Research Communications</i> , 2007, 363, 1027-1032.	1.0	45
88	Role of amino acid residue 90 in bioactivity and receptor binding capacity of tumor necrosis factor mutants. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2007, 1774, 1029-1035.	1.1	7
89	Role of tyrosine residues in modulation of claudin-4 by the C-terminal fragment of <i>Clostridium perfringens</i> enterotoxin. <i>Biochemical Pharmacology</i> , 2007, 73, 206-214.	2.0	45
90	Role of Tyr306 in the C-terminal fragment of <i>Clostridium perfringens</i> enterotoxin for modulation of tight junction. <i>Biochemical Pharmacology</i> , 2007, 73, 824-830.	2.0	33

#	ARTICLE	IF	CITATIONS
91	Quality Enhancement of the Non-immune Phage scFv Library to Isolate Effective Antibodies. Biological and Pharmaceutical Bulletin, 2006, 29, 1325-1330.	0.6	25
92	Creation of Novel Protein Transduction Domain (PTD) Mutants by a Phage Display-Based High-Throughput Screening System. Biological and Pharmaceutical Bulletin, 2006, 29, 1570-1574.	0.6	25
93	Promotion of Optimized Protein Therapy by Bioconjugation as a Polymeric DDS. Anti-Cancer Agents in Medicinal Chemistry, 2006, 6, 251-258.	0.9	8
94	Design of a pH-Sensitive Polymeric Carrier for Drug Release and Its Application in Cancer Therapy. Clinical Cancer Research, 2004, 10, 2545-2550.	3.2	64
95	Effective accumulation of poly(vinylpyrrolidone-co-vinyl laurate) into the spleen. Journal of Biomedical Materials Research Part B, 2004, 70A, 219-223.	3.0	12
96	The use of PVP as a polymeric carrier to improve the plasma half-life of drugs. Biomaterials, 2004, 25, 3259-3266.	5.7	175
97	The targeting of anionized polyvinylpyrrolidone to the renal system. Biomaterials, 2004, 25, 4309-4315.	5.7	58
98	Selective Enhancer of Tumor Vascular Permeability for Optimization of Cancer Chemotherapy. Biological and Pharmaceutical Bulletin, 2004, 27, 437-439.	0.6	5
99	Cell array coupled with laser scanning cytometry allows easy analysis of changes in cyclin expression during the cell cycle. An application of cell array system. Cytotechnology, 2002, 24, 41-47.	0.7	1
100	Effective Cancer Targeting Using an Anti-tumor Tissue Vascular Endotheliumspecific Monoclonal Antibody (TES-23). Japanese Journal of Cancer Research, 2000, 91, 1319-1325.	1.7	24
101	In Vitro Remodeling of Tumor Vascular Endothelial Cells Using Conditioned Medium from Various Tumor Cells and Their Sensitivity to TNF- α . Biochemical and Biophysical Research Communications, 2000, 268, 809-813.	1.0	16
102	Suppression of solid tumor growth by a monoclonal antibody against tumor vasculature in rats: Involvement of intravascular thrombosis and fibrinogenesis. , 1999, 82, 853-859.		8
103	Molecular Design of Conjugated Tumor Necrosis Factor- α : Synthesis and Characteristics of Polyvinyl Pyrrolidone Modified Tumor Necrosis Factor- α . Biochemical and Biophysical Research Communications, 1999, 257, 448-453.	1.0	34
104	Tumor Vascular Targeting Using a Tumor-Tissue Endothelium-Specific Monoclonal Antibody as an Effective Strategy for Cancer Chemotherapy. Biochemical and Biophysical Research Communications, 1999, 260, 346-350.	1.0	11
105	Bioconjugation of Laminin Peptide YIGSR with Poly(Styrene Co-maleic Acid) Increases Its Antimetastatic Effect on Lung Metastasis of B16-BL6 Melanoma Cells. Biochemical and Biophysical Research Communications, 1999, 255, 75-79.	1.0	45
106	Identification of tumor vascular antigens by monoclonal antibodies prepared from rat-tumor-derived endothelial cells. , 1998, 77, 561-566.		12
107	Antibody-Based Therapy Targeting Tumor Vascular Endothelial Cells Suppresses Solid Tumor Growth in Rats. Biochemical and Biophysical Research Communications, 1997, 236, 493-496.	1.0	14
108	Bioconjugation of Tumor Necrosis Factor- α with the Copolymer of Divinyl Ether and Maleic Anhydride Increasing Its Antitumor Potency. Biochemical and Biophysical Research Communications, 1997, 239, 160-165.	1.0	12

#	ARTICLE	IF	CITATIONS
109	Polyethylene glycol modification of interleukin-6 enhances its thrombopoietic activity. Journal of Controlled Release, 1995, 33, 447-451.	4.8	19
110	Characterization of PEG-IL-6 and its thrombopoietic activity in vivo.. Drug Delivery System, 1995, 10, 175-180.	0.0	2
111	Intravenous Administration of Polyethylene Glycol-modified Tumor Necrosis Factor- α Completely Regressed Solid Tumor in Meth-A Murine Sarcoma Model. Japanese Journal of Cancer Research, 1994, 85, 1185-1188.	1.7	12